Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma
CUTANEOUS AND OCULAR TOXICOLOGY, cilt.28, sa.3, ss.141-143, 2009 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 28 Sayı: 3
- Basım Tarihi: 2009
- Doi Numarası: 10.1080/15569520903046934
- Dergi Adı: CUTANEOUS AND OCULAR TOXICOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.141-143
- Anahtar Kelimeler: Bortezomib, multiple myeloma, perivascular dermatitis, response, skin lesion, vasculitic rash, VASCULITIS
- Gazi Üniversitesi Adresli: Evet
Özet
Bortezomib is a potent, selective proteasome inhibitor. It is usually well tolerated, and bortezomib-induced skin lesions are less well known. A 59-year-old man with multiple myeloma underwent autologous hematopoetic stem cell transplantation (AHSCT). Administration of bortezomib was started after AHSCT as his disease progressed despite thalidomide maintenance. He developed a rash afer the third cycle of bortezomib. A biopsy showed superficial and deep perivascular dermatitis. The rash resolved within 4 days; complete response of myeloma was obtained after 8 cycles of bortezomib. The benign clinical course did not require interruption of the treatment, which in turn resulted in complete remission of myeloma.